



Frequency and Duration **MATTER**



NxStage® System One™

FIRST and ONLY clearance for
Home Nocturnal Hemodialysis

MANAGING CLINICAL NEEDS

More frequent dialysis, during the day (HHD) or overnight (NHD), may provide significant clinical and quality of life benefits including:

- More energy¹⁻⁴
- Improved appetite^{3,5-9}
- Quicker time to recovery^{10,11}
- Lower risk of death¹²⁻¹⁷

More frequent home hemodialysis, with the NxStage System One, may help to reduce the amount of toxin and water build-up between treatments. This may reduce or even eliminate the many side effects patients experience with conventional three-times-weekly therapy.

CLINICAL BENEFITS	FREQUENT HHD	FREQUENT NOCTURNAL HD
Improved survival	+ ¹²⁻¹⁶	++ ¹⁷
Better middle to large molecule clearance	/	+ ^{18,19}
Improved phosphorus control	+ ²⁰⁻²²	++ ^{9,23}
Quicker recovery time after treatment	+ ^{10,11}	++ ²
Better mental and physical health	+ ^{1-4,20,24,25}	++ ²⁶
Increased likelihood of transplantation	+ ²⁷	+ ²⁷
Moderate interdialytic fluid gain	+ ^{3,5-8}	+ ²⁸
Reduced left ventricular hypertrophy	+ ^{7,20,21,29}	+ ^{28,29}
Less myocardial stunning	+ ³²	++ ³²
Better blood pressure control with fewer medications	+ ^{3,7,20,29,33-35}	+ ^{30,31,36}

Legend: / Negligible | + Moderate | ++ Substantial

Indexed to conventional in-center hemodialysis

The evidence is clear. Clinical studies have shown that patients performing more frequent hemodialysis with the NxStage System One may live longer, experience shortened time to recovery and feel better both mentally and physically. ^{1,10,12,13,33}

IMPROVING QUALITY OF LIFE

The flexible therapy option of performing treatments during the day or overnight gives patients control over their schedule. Without rigid dialysis clinic time-slots to contend with, patients may be able to resume working, travel or spend more time with their friends and family. This is in addition to a number of other lifestyle benefits.

LIFESTYLE BENEFITS	IN-CENTER NOCTURNAL HD	FREQUENT HHD	FREQUENT HOME NOCTURNAL HD
Better supports working patients / care partners	++	+	++
Reclaim their day	++	+	++
Quicker recovery time after treatment	++ ²	+ ^{10,11}	++ ²
More energy	++ ²	+ ¹⁻⁴	++ ²
Improved sleep quality	+ ³⁷	+ ^{3,38,39}	+ ³⁷
Liberalized diet and fluid intake restrictions	++ ^{9,28}	+ ^{3,5-9}	++ ^{9,28}
Lessened dependency on others	/	++ ²	++ ²
Choice of privacy / discretion	/	+	+
Reduced visits to the clinic	/	+	+
Lessen exposure to communicable diseases	/	+	+
Increased ability to travel*	/	+	+
Improved sexual satisfaction	+ ^{2,40}	+ ^{1,2,4,41}	+ ^{2,40}

Legend: / Negligible | + Moderate | ++ Substantial

Indexed to conventional in-center hemodialysis

*Available with the NxStage System One

THE SYSTEM ONE DIFFERENCE

The NxStage System One was designed as a **SIMPLE, FLEXIBLE, AND PORTABLE** system, without compromising safety, providing the growing number of people with end-stage renal disease better options for their hemodialysis treatments.



Express System

HOW THE NXSTAGE SYSTEM ONE WORKS

- 1 NO SPECIAL INFRASTRUCTURE REQUIREMENTS**
 - » Plugs into a standard electrical outlet
 - » Drains without requiring plumbing changes
- 2 DESIGNED FOR EASE OF SET-UP, TRAINING, AND PORTABILITY**
 - » Drop-in cartridge allows one-step loading
 - » Patient-friendly controls
 - » Simple, compact PureFlow SL water purification system
 - » Prepackaged fluids giving patients the freedom to travel or dialyze throughout their home
- 3 SIMPLE MAINTENANCE**
 - » Quick, wipe-down disinfection makes maintenance easy
 - » NxStage service swap program helps prevent missed treatments
- 4 DEDICATED SUPPORT**
 - » NxStage support representatives available 24/7

NxStage System One

FIRST and ONLY clearance for Home Nocturnal Hemodialysis

FLEXIBLE THERAPY AT YOUR FINGERTIPS

Calculating dialysis prescriptions has never been easier. Designed and built from scientific formulas and peer-reviewed journals, the NxStage Dosing Calculator provides flexible treatment schedules to assist you in prescribing the therapy option that works best for your patients.

Now when discussing options with your patients you can work together to see what fits into their schedules while meeting their clinical needs.

Compatible with desktop and mobile devices,

the Dosing Calculator is available when and where you need it.

Language: English-United States (English) SIGN OUT

NxSTAGE
Treat. Improve. Inspire.

NxStage Dosing Calculator

Use Watson Body Water Calculator?
 Yes
 No

Watson Body Water Calculator
Age: 63
Weight: 115 lb
Height: 74 in
Gender: Male Female
Volume (V): 55

Treatment Calculator
Target weekly stdKtV: 2.0
Blood flow rate: 500 ml/min
Hematocrit: 34
Weekly UF volume: 1.2
Max UF Rate: 1.1
Min hours/week: 1.0
Allow 3-days per week: Yes No
Round up to nearest SAK: Yes No
Include rinsback in daily UF: Yes No

Calculate



TRY THE DOSING CALCULATOR TODAY
DOSINGCALCULATOR.NXSTAGE.COM

WHAT WOULD YOU DO?

In a survey of 78 dialysis center medical directors, **98%** reported that they would choose a home modality if they needed dialysis.⁴²

FOR MORE INFORMATION VISIT: NXSTAGE.COM OR CALL 1-866-NXSTAGE.

Despite the health benefits that more frequent home hemodialysis may provide to those with chronic kidney disease, this form of therapy is not for everyone. Home hemodialysis with the NxStage System One requires a patient and partner who are committed to being trained on and following the guidelines for proper system operation.

The reported benefits of home hemodialysis may not be experienced by all patients.

The NxStage System One is a prescription device and, like all medical devices, involves some risks. The risks associated with hemodialysis treatments in any environment include, but are not limited to, high blood pressure, fluid overload, low blood pressure, heart-related issues, and vascular access complications. The medical devices used in hemodialysis therapies may add additional risks including air entering the bloodstream, and blood loss due to clotting or accidental disconnection of the blood tubing set. Patients should consult with their doctor to understand the risks and responsibilities of home and/or more frequent hemodialysis using the NxStage System One.

Certain risks are unique to the home. Treatments at home are done without the presence of medical personnel and on-site technical support. Patients and their partners must be trained on what to do and how to get medical or technical help if needed.

Certain risks associated with hemodialysis treatment are increased when performing nocturnal therapy due to the length of treatment time and because therapy is performed while the patient and care partner are sleeping. These risks include, but are not limited to, blood access disconnects and blood loss during sleep, blood clotting due to slower blood flow or increased treatment time or both, and delayed response to alarms when waking from sleep. Patients should consult with their physician to understand the risks and responsibilities associated with home nocturnal hemodialysis using the NxStage System One.

REFERENCES:

1. Finkelstein FO, Schiller B, Daoui R, et al. At-home short daily hemodialysis improves the long-term health-related quality of life. *Kidney Int.* 2012;82(5):561-569.
2. Heidenheim PA, Muirhead N, Moist L, Lindsay RM. Patient quality of life on quotidian hemodialysis. *Am J Kidney Dis.* 2003;42(S1):S36-S41.
3. Ting GO, Kjellstrand C, Freitas T, Carrie BJ, Zarghamee S. Long-term study of high-comorbidity ESRD patients converted from conventional to short daily hemodialysis. *Am J Kidney Dis.* 2003;42(5):1020-1035.
4. Goldfarb-Rumyantzev AS, Leyboldt JK, Nelson N, Kutner NG, Cheung AK. A crossover study of short daily haemodialysis. *Nephrol Dial Transplant.* 2006;21:166-175.
5. Spanner E, Suri R, Heidenheim AP, Lindsay RM. The impact of quotidian hemodialysis on nutrition. *Am J Kidney Dis.* 2003;42(1 suppl):30-35.
6. Galland R, Traeger J, Arkouche W, Cleaud C, Delawari E, Fouque D. Short daily hemodialysis rapidly improves nutritional status in hemodialysis patients. *Kidney Int.* 2001;60(4):1555-1560.
7. Traeger J, Galland R, Delawari E, Arkouche W, Hadden R. Six years' experience with short daily hemodialysis: do the early improvements persist in the mid and long term? *Hemodial Int.* 2004;8(2):151-158.
8. Buoncristiani U. Fifteen years of clinical experience with daily haemodialysis. *Nephrol Dial Transplant.* 1998;13(suppl 6):148-151.
9. Williams AW, O'Sullivan DA, McCarthy JT. Slow nocturnal and short daily hemodialysis: a comparison. *Semin Dial.* 1999;12(6):431-439.
10. Jaber BL, Lee Y, Collins AJ, et al. Effect of daily hemodialysis on depressive symptoms and postdialysis recovery time: interim report from the FREEDOM (Following Rehabilitation, Economics and Everyday-Dialysis Outcome Measurements) Study. *Am J Kidney Dis.* 2010;56(3):531-539.
11. Lindsay RM, Heidenheim PA, Nesrallah G, Garg AX, Suri R. Daily Hemodialysis Study Group London Health Sciences Centre. Minutes to recovery after a hemodialysis session: a simple health-related quality of life question that is reliable, valid, and sensitive to change. *Clin J Am Soc Nephrol.* 2006;1(6):952-959.
12. Weinhandl ED, Lie J, Gilbertson DT, Arneson TJ, Collins AJ. Survival in daily home hemodialysis and matched thrice-weekly in-center hemodialysis patients. *J Am Soc Nephrol.* 2012;23(5):895-904.
13. Miller BW, Collins AJ, Finkelstein FO, et al. Daily hemodialysis (DHD) is associated with lower than expected mortality. Abstract presented as poster at American Society of Nephrology Conference, October 29, 2009.
14. Blagg CR, Kjellstrand CM, Ting GO, Young BA. Comparison of survival between short-daily hemodialysis and conventional hemodialysis using the standardized mortality ratio. *Hemodial Int.* 2006;10(4):371-374.
15. Kjellstrand CM, Buoncristiani U, Ting G, et al. Short daily haemodialysis: survival in 415 patients treated for 1006 patient-years. *Nephrol Dial Transplant.* 2008;23(10):3283-3289.
16. Woods JD, Port FK, Stannard D, Blagg CR, Held PJ. Comparison of mortality with home hemodialysis and center hemodialysis: a national study. *Kidney Int.* 1996;49(5):1464-1470.
17. Pauly RP, Gill JS, Rose CL, et al. Survival among nocturnal home haemodialysis patients compared to kidney transplant recipients. *Nephrol Dial Transplant.* 2009;24:2915-2919.
18. Eloit S, Van Biesen W, Dhondt A, et al. Impact of hemodialysis duration on the removal of uremic retention solutes. *Kidney Int.* 2008;73:765-770.
19. Raj DS, Ouwendyk M, Francoeur R, Pierratos A. 2-Microglobulin kinetics in nocturnal haemodialysis. *Nephrol Dial Transplant.* 2000;15(1):58-64.
20. FHN Trial Group. In-center hemodialysis six times per week versus three times per week. *N Engl J Med.* 2010;363(24):2287-2300.
21. Ayus JC, Mizani MR, Achinger SG, et al. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. *J Am Soc Nephrol.* 2005;16(9):2778-2388.
22. Ayus JC, Achinger SG, Mizani MR, et al. Phosphorus balance and mineral metabolism with 3 h daily hemodialysis. *Kidney Int.* 2007;71(4):336-342.
23. Mucsi I, Hercz G, Uldall R, et al. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. *Kidney Int.* 1998;53(5):1399-1404.
24. Hall YN, Larive B, Painter P, et al. Effects of six versus three times per week hemodialysis on physical performance, health, and functioning: Frequent Hemodialysis Network (FHN) randomized trials. *Clin J Am Soc Nephrol.* 2012;7(5):782-794.
25. Puñal Riobó J, Sánchez-Iriso E, Ruano-Ravina A, et al. Short daily versus conventional hemodialysis quality of life: a cross-sectional multicentric study in Spain. *Blood Purif.* 2009;28(3):159-164.
26. Chan CT, Notarius CF, Merlocco AC, et al. Improvement in exercise duration and capacity after conversion to nocturnal home haemodialysis. *Nephrol Dial Transplant.* 2007;22(11):3285-3291.
27. Weinhandl E, Liu J, Gilbertson D, Arneson T, Collins A. Transplant incidence in frequent hemodialysis and matched thrice-weekly hemodialysis patients. Poster presented at National Kidney Foundation Spring Clinical Meeting, 2012.
28. Pierratos A. Daily (quotidian) nocturnal home hemodialysis: *Nine years later.* *Hemodial Int.* 2004;8(1):45-50.
29. Fagugli RM, Rebaldi G, Quintaliani G, et al. Short daily hemodialysis: blood pressure control and left ventricular mass reduction in hypertensive hemodialysis patients. *Am J Kidney Dis.* 2001;38(2):371-376.
30. Culleton BF, Walsh M, Klarenbach SW, et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life. *JAMA.* 2007; 298(11):1291-1299.
31. Chan CT, Floras JS, Miller JA, Richardson RM, Pierratos A. Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. *Kidney Int.* 2002;61:2235-2239.
32. Jefferies HJ, Virk B, Schiller B, Moran J, McIntyre CW. Frequent hemodialysis schedules are associated with reduced levels of dialysis-induced cardiac injury (Myocardial stunning). *Clin J Am Soc Nephrol.* 2011;6(6): 1326-1332.
33. Kraus M, Burkart J, Hegeman R, Solomon R, Coplon N, Moran J. A comparison of center-based vs. home-based daily hemodialysis for patients with end-stage renal disease. *Hemodial Int.* 2007;11(4):468-477.
34. Nesrallah G, Suri R, Moist L, Kortas C, Lindsay RM. Volume control and blood pressure management in patients undergoing quotidian hemodialysis. *Am J Kidney Dis.* 2003;42(1 suppl):13-17.
35. Reynolds JT, Homel P, Cantey L, et al. A one-year trial of in-center dialy hemodialysis with an emphasis on quality of life. *Blood Purif.* 2004;22(3):320-328.
36. Lindsay RM, Leitch R, Heidenheim AP, Kortas C. The London daily/nocturnal hemodialysis study—study design, morbidity, and mortality results. *Am J Kidney Dis.* 2003;42(suppl 1):S5-S12.
37. Hanly PJ, Pierratos A. Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis. *N Engl J Med.* 2001;344(2):102-107.
38. Elias RM, Castro MC, de Queiroz EL, Abensur H, Romão JE Jr, Lorenzi-Filho G. Obstructive sleep apnea in patients on conventional and short daily hemodialysis. *Am J Nephrol.* 2009;29(6):493-500.
39. Jaber BL, Schiller B, Burkart JM, et al. Impact of short daily hemodialysis on restless legs symptoms and sleep disturbances. *Clin J Am Soc Nephrol.* 2011;6(5):1049-1056.
40. Lockridge RS, Spencer M, Craft V, et al. Nightly home hemodialysis: five and one-half years of experience in Lynchburg, Virginia. *Hemodial Int.* 2004;8:61-69.
41. Kraus M, Finkelstein FO, Daoui R, et al. Short Daily Hemodialysis (SDHD) improves overall Quality of Life (QOL) and physical intimacy: interim results from the FREEDOM study. Abstract presented at the American Society of Nephrology Conference, 2011.
42. Schiller B, Neitzer A, Doss S. Perceptions about renal replacement therapy among nephrology professionals. *Nephrol News Issues.* 2010; 24(10):36-44.



NxStage Medical, Inc. • 350 Merrimack Street, Lawrence, MA 01843 • 1-866-NxStage (1-866-697-8243)

© 2017 NxStage Medical, Inc. NxStage is a registered trademark of NxStage Medical, Inc. System One and PureFlow are trademarks of NxStage Medical, Inc. CAUTION: Federal law restricts this device to sale by or on the order of a physician. APM1523 Rev. A2